This article is more than 5 years old. Information may no longer be current.
Lower HDL not associated with increased risk for ischemic heart disease
Click Here to Manage Email Alerts
Lower plasma levels of HDL cholesterol due to heterozygosity for loss-of-function mutations in ABCA1 were not associated with an increased risk for ischemic heart disease, according to the findings from a recent study.
The researchers from Denmark and other sites conducted a study to determine if genetically reduced HDL cholesterol due to heterozygosity for four loss-of-function mutations in ABCA1 increased the risk for ischemic heart disease.
They examined data from the Copenhagen City Heart Study (n=9,022; 28 heterozygotes), the Copenhagen General Population Study (n=31,241; 76 heterozygotes) and the Copenhagen Ischemic Heart Disease Study (n=16,623; 44 heterozygotes).
Heterozygotes had HDL levels of 41 mg/dL; with noncarriers had HDL levels of 58 mg/dL). A 17 mg/dL lower HDL level in the Copenhagen City Heart Study was associated with a multifactorially adjusted hazard ratio for ischemic heart disease (1.70; 95% CI, 1.57-1.85), according to the researchers.
In heterozygotes and noncarriers, the hazard ratio was 0.67 (95% CI, 0.28-1.61) in the Copenhagen City Heart Study, 0.82 (95% CI, 0.34-1.96) in the Copenhagen General Population Study and 0.86 (95% CI, 0.32-2.32) in the Copenhagen Ischemic Heart Disease Study. For the studies combined, the hazard ratio was 0.93 (95% CI, 0.53-1.62)
In the Copenhagen City Heart Study, there were 1,741 ischemic heart disease events; in the Copenhagen General Population Study, there were 2,427 ischemic heart disease events, and in the Copenhagen Ischemic Heart Disease Study, there were 2,498 ischemic heart disease events. – by Christen Haigh
JAMA. 2008;299:2524-2532.